1. Product Overview & Specifications

2. Key Applications & Mechanism of Action

Therapeutic Applications

• HIV-1 Treatment: Potent inhibitor of HIV-1 protease (Ki = 1.3 pM), blocking viral maturation and infectivity.
• Antiviral Research: Inhibits SARS-CoV 3CL protease (IC₅₀ = 14.2 μM) for coronavirus studies.

Non-Therapeutic Uses

• Pharmaceutical reference standard (USP/EP) for HPLC analysis and quality control.
• Research reagent for protease inhibition assays.

3. Usage Guidelines & Best Practices

Formulation Recommendations

• Co-administered with ritonavir (100–400 mg/day) to enhance bioavailability.
• DMSO stock solutions (10 mM) stable for ≤1 month at -20°C.

Safety & Handling

• Hygroscopic material – store in desiccated conditions.
• UN 3077 classification – non-hazardous for transport.

4. Industry Case Studies

Case 1: Pharmaceutical QC Laboratory

Client: Shanghai Jieruixing Bio-Tech
Application: USP/EP standard for batch analysis of HIV protease inhibitors.
Outcome: Achieved 99.58% purity validation across 12 production batches.

Case 2: Virology Research Institute

Client: Beijing BioLab Technologies
Application: SARS-CoV-2 3CLpro inhibition screening.
Outcome: Identified 72% viral replication inhibition at 20 μM concentration.

5. Technical Support & Inquiry

For bulk orders (>100g), custom purity grades (98–99.9%), or regulatory documentation: